Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy (Q37664705)

21 August 2017

1 reference

title

Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy (English)

1 reference

serotonin–norepinephrine reuptake inhibitor

21 August 2017

0 references

0 references

1 reference

Massimiliano Buoli

2

0 references

Bernardo Dell'Osso

object named as

Bernardo Dell'Osso

series ordinal

1

0 references

A. Carlo Altamura

series ordinal

4

object named as

A Carlo Altamura

1 reference

21 August 2017

David S Baldwin

3

1 reference

21 August 2017

1 January 2010

1 reference

21 August 2017

Human Psychopharmacology

1 reference

21 August 2017

25

1 reference

21 August 2017

1

1 reference

21 August 2017

17-29

1 reference

Neurobiology of fear responses: the role of the amygdala

21 August 2017

1 reference

Prevalence of common mental disorders in Italy: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD).

21 January 2018

1 reference

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

Anxiety disorders in primary care: prevalence, impairment, comorbidity, and detection.

21 January 2018

1 reference

Length of therapy with selective serotonin reuptake inhibitors and tricyclic antidepressants in Australia

21 January 2018

1 reference

Pharmacology and pharmacokinetics of milnacipran

21 January 2018

1 reference

WCA Recommendations for the Long-Term Treatment of Generalized Anxiety Disorder

21 January 2018

1 reference

7 January 2021

Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study

1 reference

7 January 2021

Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.

1 reference

7 January 2021

Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine

1 reference

7 January 2021

Venlafaxine in social phobia: a study in selective serotonin reuptake inhibitor non-responders

1 reference

7 January 2021

Duration of untreated illness as a predictor of treatment response and clinical course in generalized anxiety disorder.

1 reference

7 January 2021

The generalized anxiety spectrum: prevalence, onset, course and outcome

1 reference

7 January 2021

The use of benzodiazepines in anxiety and other disorders

1 reference

7 January 2021

Sexual dysfunction associated with antidepressant drugs

1 reference

7 January 2021

Evidence-based guidelines for anxiety disorders: can they improve clinical outcomes?

1 reference

7 January 2021

Role of pregabalin in the treatment of generalized anxiety disorder

1 reference

7 January 2021

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

1 reference

7 January 2021

Resolution of sexual dysfunction during acute treatment of major depression with milnacipran

1 reference

7 January 2021

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

1 reference

7 January 2021

The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy

1 reference

7 January 2021

1 reference

7 January 2021

Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment

1 reference

7 January 2021

The efficacy of milnacipran in panic disorder: an open trial

1 reference

7 January 2021

Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder

1 reference

7 January 2021

Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study

1 reference

7 January 2021

Treatment of patients comorbid for addiction and other psychiatric disorders

1 reference

7 January 2021

Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies

1 reference

7 January 2021

Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder

1 reference

7 January 2021

Clinical and psychosocial outcome of patients affected by panic disorder with or without agoraphobia: results from a naturalistic follow-up study.

1 reference

7 January 2021

Duloxetine in the treatment of panic disorder

1 reference

7 January 2021

Duloxetine in the treatment of social anxiety disorder

1 reference

7 January 2021

A naturalistic long-term comparison study of selective serotonin reuptake inhibitors in the treatment of panic disorder

1 reference

7 January 2021

Pharmacotherapy of social phobia.

1 reference

7 January 2021

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder

1 reference

7 January 2021

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial

1 reference

7 January 2021

Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study

1 reference

7 January 2021

Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial

1 reference

7 January 2021

5-HT and mechanisms of defence

1 reference

7 January 2021

Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder

1 reference

7 January 2021

Milnacipran: an antidepressant with dual selectivity of action on noradrenaline and serotonin uptake.

1 reference

7 January 2021

Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series

1 reference

7 January 2021

Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: A critical review.

1 reference

7 January 2021

Anxiety in primary care

1 reference

7 January 2021

A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder

1 reference

7 January 2021

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

1 reference

7 January 2021

Functional neuroimaging of anxiety: a meta-analysis of emotional processing in PTSD, social anxiety disorder, and specific phobia

1 reference

7 January 2021

Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients

1 reference

7 January 2021

Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release.

1 reference

7 January 2021

The descriptive epidemiology of obsessive-compulsive disorder.

1 reference

7 January 2021

Efficacy of milnacipran in treating anxiety symptoms in schizophrenic patients receiving clozapine: a case series study

1 reference

7 January 2021

Adverse Drug Events in Ambulatory Care

1 reference

7 January 2021

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

1 reference

7 January 2021

Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder

1 reference

7 January 2021

Neurobiology of panic disorder: from animal models to brain neuroimaging

1 reference

7 January 2021

Antidepressant-induced sexual dysfunction

1 reference

7 January 2021

Combined use of ECT with duloxetine and olanzapine: a case report

1 reference

7 January 2021

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial

1 reference

7 January 2021

A review and meta-analysis of the genetic epidemiology of anxiety disorders

1 reference

7 January 2021

Antidepressants in long-term therapy: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors

1 reference

7 January 2021

Venlafaxine in treatment-resistant obsessive-compulsive disorder.

1 reference

7 January 2021

Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder

1 reference

7 January 2021

The neurobiology of anxiety disorders.

1 reference

7 January 2021

The role of the central nucleus of the amygdala in mediating fear and anxiety in the primate

1 reference

7 January 2021

Recent advances in GABA research

1 reference

7 January 2021

A meta-analysis of structural brain abnormalities in PTSD.

1 reference

7 January 2021

Posttraumatic stress disorder: etiology, epidemiology, and treatment outcome.

1 reference

7 January 2021

Dose-response relationship with venlafaxine

1 reference

7 January 2021

SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression

1 reference

7 January 2021

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group

1 reference

7 January 2021

Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder

1 reference

7 January 2021

Efficacy of duloxetine for the treatment of generalized anxiety disorder: implications for primary care physicians

1 reference

7 January 2021

Synthesis and biological activity of some known and putative duloxetine metabolites

1 reference

7 January 2021

Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects

1 reference

7 January 2021

Fear and the brain: where have we been, and where are we going?

1 reference

7 January 2021

The functional neuroanatomy of PTSD: a critical review

1 reference

7 January 2021

The epidemiology of generalized anxiety disorder in Europe

1 reference

7 January 2021

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder

1 reference

7 January 2021

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

1 reference

7 January 2021

Remission, dropouts, and adverse drug reaction rates in major depressive disorder: a meta-analysis of head-to-head trials

1 reference

7 January 2021

Neural correlates of anxiety associated with obsessive-compulsive symptom dimensions in normal volunteers.

1 reference

7 January 2021

Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder.

1 reference

7 January 2021

Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study

1 reference

7 January 2021

Neurons in medial prefrontal cortex signal memory for fear extinction

1 reference

7 January 2021

Effects of milnacipran in animal models of anxiety and memory.

1 reference

7 January 2021

The role of anticonvulsant drugs in anxiety disorders: a critical review of the evidence

1 reference

7 January 2021

Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis

1 reference

7 January 2021

Open trial of milnacipran for Taijin-Kyofusho in Japanese patients with social anxiety disorder

1 reference

7 January 2021

Efficacy and tolerability of milnacipran in the treatment of major depression in comparison with other antidepressants : a systematic review and meta-analysis.

1 reference

7 January 2021

The role of the amygdala in human fear: automatic detection of threat

1 reference

7 January 2021

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

1 reference

7 January 2021

Traumatic events and post-traumatic stress disorder in the community: prevalence, risk factors and comorbidity

1 reference

7 January 2021

A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder.

1 reference

7 January 2021

Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor

1 reference

7 January 2021

Pharmacokinetics of milnacipran in liver impairment

1 reference

7 January 2021

Pharmacokinetics of milnacipran in renal impairment

1 reference

7 January 2021

Prevalence of anxiety disorders and their comorbidity with mood and addictive disorders

1 reference

7 January 2021

Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders

1 reference

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

7 January 2021

A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder

1 reference

7 January 2021

Neuropharmacology of venlafaxine

1 reference

7 January 2021

Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors

1 reference

7 January 2021

A meta-analysis of the effects of venlafaxine on anxiety associated with depression.

1 reference

7 January 2021

Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.

1 reference

7 January 2021

Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.

1 reference

7 January 2021

Neurobiologic basis of anxiety and its treatment

1 reference

7 January 2021

Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder

1 reference

7 January 2021

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder

1 reference

7 January 2021

Use of benzodiazepines in anxiety disorders

1 reference

7 January 2021

Amygdala, medial prefrontal cortex, and hippocampal function in PTSD

1 reference

7 January 2021

Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis

1 reference

7 January 2021

Desvenlafaxine: another "me too" drug?

1 reference

7 January 2021

Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects

1 reference

7 January 2021

Why settle for silver, when you can go for gold? Response vs. recovery as the goal of antidepressant therapy

1 reference

7 January 2021

Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression

1 reference

7 January 2021

Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial

1 reference

7 January 2021

Effects of the serotonin and noradrenaline reuptake inhibitor (SNRI) milnacipran on marble burying behavior in mice

1 reference

7 January 2021

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

1 reference

7 January 2021

The anatomy of fear extinction.

1 reference

7 January 2021

Antiepileptic drugs in the treatment of anxiety disorders: role in therapy

1 reference

7 January 2021

Antidepressants and sexual dysfunction.

1 reference

7 January 2021

A functional magnetic resonance imaging predictor of treatment response to venlafaxine in generalized anxiety disorder.

1 reference

7 January 2021

A meta-analysis of functional neuroimaging in obsessive-compulsive disorder

1 reference

7 January 2021

Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies

1 reference

7 January 2021

Size and burden of mental disorders in Europe—a critical review and appraisal of 27 studies

1 reference

7 January 2021

PET in generalized anxiety disorder

1 reference

7 January 2021

Venlafaxine in obsessive-compulsive disorder

1 reference

7 January 2021

Chronicity, relapse, and illness--course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up.

1 reference

7 January 2021

[Anticonvulsants in the treatment of anxiety--an alternative treatment option?]

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.1074

1 reference

21 August 2017

1 reference

PubMed ID

20041476